DTaP poliovirus vaccine - Sanofi Pasteur

Drug Profile

DTaP poliovirus vaccine - Sanofi Pasteur

Alternative Names: DTacP-IPV combined vaccine - Sanofi; Tetravac; Tetraxim

Latest Information Update: 04 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aventis Pasteur (now called sanofi pasteur)
  • Developer Sanofi Pasteur
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 03 Mar 2014 Launched prior to 2014 for Diphtheria (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)
  • 03 Mar 2014 Launched prior to 2014 for Tetanus (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)
  • 03 Mar 2014 Launched prior to 2014 for Pertussis (prevention, in infants and children) in Argentina, Austria, Belgium, Finland, France, Germany, Greece, Italy, Hong Kong, Hungary, Ireland, Malaysia, Norway, Philippines, Portugal, South Africa, South Korea, Switzerland, Thailand, Turkey and the United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top